H.R. 7871 119th Congress House

MVP Act

Official title: To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting u… Show full official titleShow less

Official title: To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.

Introduced: March 9, 2026 Introduced by: Brett Guthrie Republican · Kentucky See on congress.gov

Health

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 9, 2026

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 9, 2026

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now March 9, 2026

Plain-English summary Congressional Research Service

Medicaid VBPs for Patients Act or the MVP Act

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.

Related & companion bills 1

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 2

Energy and Commerce Committee
House of Representatives
Ways and Means Committee
House of Representatives

Lobbying activity 20

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

BIOTECHNOLOGY INNOVATION ORGANIZATION
for BIOTECHNOLOGY INNOVATION ORGANIZATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
for AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
BAYER CORPORATION (CONSOLIDATED REPORT)
for BAYER CORPORATION (CONSOLIDATED REPORT) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
MONUMENT ADVOCACY
for COUNCIL FOR AFFORDABLE HEALTH COVERAGE · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
GRIDIRON PUBLIC AFFAIRS, LLC
for BEAM THERAPEUTICS · Massachusetts · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

HOUSE OF REPRESENTATIVES
20 filings
SENATE
20 filings
Health & Human Services, Dept of (HHS)
13 filings
Centers For Medicare and Medicaid Services (CMS)
12 filings
Executive Office of the President (EOP)
8 filings
Labor, Dept of (DOL)
7 filings
Food & Drug Administration (FDA)
5 filings
Office of Management & Budget (OMB)
4 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 20 filings →

Cosponsors 17